medigraphic.com
Patología Revista Latinoamericana

2012, Number 2

<< Back Next >>

Patol Rev Latinoam 2012; 50 (2)

Triple Marker Immunohistochemestry Analysis in Breast Cancer Mexican Patients

Calderón-Garcidueñas AL, Martínez-Reyes G, Gallardo-Gómez AI, Rojas-Martínez A, Cerda-Flores RM

Language: English
References: 27
Page: 72-79
PDF size: 327.84 Kb.


ABSTRACT

Objective: To assess the different expression profiles of ductal BC in Mexican women based on IHC analysis of three markers (ER, PR, and HER2) and to compare them between women with EOBC (≤35 years of age at diagnosis) and patients over 35 years.
Methodology: All consecutive, new cases of invasive ductal carcinoma not otherwise specified, registered at the Pathology Department files were selected for study. General frequencies of each marker were determined and different profiles in tumor tissue samples were obtained.
Results: 506 tumor samples were studied; 43 of them from women with EOBC (8.5%). The IHC profiles of tumors were: triple negative, 19.1%; HER2, 16.6%; luminal A, 56.3%, and luminal B, 8%. Women with EOBC and older patients have significantly different profiles. The triple negative, the HER2-overexpressing, and the luminal B, ER+PR- profiles were more frequent in young women, and they were associated with higher histological grade. The frequency of the triple negative group (19.1%) was higher than usually reported (15%). Majority of triple negative cases had high histological grades (II or III). However, 2.1 % were well differentiated tumors. HER2-overexpressing profile predominated in the EOBC (28%) while the other group showed almost half of this frequency (15.5%).
Conclusion: Expression profiles in Mexican women have special features. These findings justify a prospective clinical study in order to determine the biological behavior of the different profiles. This evaluation is important for therapeutic decisions and the quality of life in women from developing countries where expensive diagnostic techniques are not available for all patients.


REFERENCES

  1. Maalej M, Hentati D, Messai T et al. Breast cancer in Tunisia in 2004: a comparative clinical and epidemiological study. Bull Cancer. 2008; 95(2):E5-E9.

  2. Secretaría de Salud. Registro histopatológico de neoplasias malignas compendio de mortalidad/morbilidad.1984–2006, México.

  3. Rodríguez Cuevas SA, Capurso García M. Epidemiology of breast cancer. Ginecol Obstet Mex. 2006;74(11):585-593.

  4. Breast. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual. 7a. edición. New York: Springer, 2010. pp. 347-376.

  5. Kolble K. Morphological detection of hormone and growth factor receptors in breast cancer. Recent Results Cancer Res 2007;176:201-209.

  6. Rosenthal SI, Depowski PL, Sheehan CE, et al. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol. 2002;10(1):40-6.

  7. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 2003;100(14):8418-8423.

  8. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869-10874.

  9. Del Casar JM, Martín A, García C, et al. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: Relationship with clinicopathological characteristics, biological features and prognosis. Eur J Obstet Gynecol Reprod Biol 2008;141(2):147-152.

  10. Lorenzo Melchor L, Benítez J. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Carcinogenesis 2008;29(8):1475-82.

  11. Nakajima H, Fujiwara I, Mizuta N, et al. Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining. World J Surg 2008;32(11):2477-2482.

  12. Calderón-Garcidueñas AL, Rivera-Prieto RA, Ortíz-López R, et al. Genetic structure of Mexican Mestizo women with breast cancer based on three STR loci. Am J Hum Biol 2008;20(2):191-193.

  13. Calderón-Garcidueñas AL, Ruiz-Flores P, Cerda-Flores RM, Barrera-Saldaña HA. Clinical follow up of Mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. Salud Pub Mex 2005;47(2):110-115.

  14. Le Doussal V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64(9):1914-1921.

  15. Goldhirsch A, Glick JH, Gelber RD, et al, Panel members. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16(10):1569-1583.

  16. Kurosumi M. Immunohistochemical assessment of hormone receptor status using a new scoring system (J-Score) in breast cancer. Breast Cancer 2007;14(2):189-93.

  17. Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer. 2010;10:534.

  18. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131(1):18-43.

  19. Roff DA, Bentzen P. The statistical analysis of mitochondria DNA polymorphisms: X2 and the problem of small samples. Mol Biol Evol1989;6:539-545.

  20. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216(2):141-150.

  21. Ratnatunga N, Liyanapathirana LV. Hormone receptor expression and Her/2neu amplification in breast carcinoma in a cohort of Sri Lankans. Ceylon Med J 2007;52(4):133-136.

  22. Riemer AB, Zielinski CC. Use of trastuzumab in the therapy of breast cancer. Ther Umsch 2008;65(4):217-222.

  23. Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25(30):4772-4778.

  24. Stefansson OA, Jonasson JG, Olafsdottir K, Hilmarsdottir H, Olafsdottir G, Esteller M, Johannsson OT, Eyfjord JE. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 2011;6(5):638-649.

  25. Kwan M, Kushi L, Weltzien E, Maring B, Kutner S, Fulton R, Lee M, Ambrosone C, Caan B. Epidemiology of breast cancer subtypes in two prospective cohort Studies of breast cancer survivors. Breast Cancer Research 2009;11:R31.

  26. Pazaiti A, Fentiman IS. Basal phenotype breast cancer: implications for treatment and prognosis. Womens Health (Lond Engl) 2011;7(2):181-202.

  27. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, González-Angulo AM, Bargalló E, Aguilar JL, Mohar A, Arrieta O. Triple-negative breast cancer in hispanic patients: High prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 2011 doi:10.1002/cncr.25961.




2020     |     www.medigraphic.com